Arcus Biosciences’ (NYSE:RCUS) quiet period is set to end on Tuesday, April 24th. Arcus Biosciences had issued 8,000,000 shares in its public offering on March 15th. The total size of the offering was $120,000,000 based on an initial share price of $15.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Several equities analysts recently weighed in on RCUS shares. Goldman Sachs started coverage on Arcus Biosciences in a research report on Monday, April 9th. They set a “neutral” rating and a $18.00 price objective for the company. Leerink Swann started coverage on Arcus Biosciences in a research report on Monday, April 9th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Citigroup started coverage on Arcus Biosciences in a research report on Monday, April 9th. They set a “buy” rating and a $18.00 price objective for the company.
NYSE RCUS opened at $16.71 on Tuesday. Arcus Biosciences has a twelve month low of $13.26 and a twelve month high of $22.10.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.chaffeybreeze.com/2018/04/17/arcus-biosciences-incs-quiet-period-to-end-on-april-24th-nysercus.html.
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.